Where’s The Suffix? Valeant’s Siliq Approved Without Four-Letter Identifier
Executive Summary
Psoriasis treatment brodalumab is first novel biologic approved since US FDA released its final guidance on nonproprietary naming for new biologics and biosimilars; agency says it didn't want to delay the approval by taking more time to develop a suffix.
You may also be interested in...
Keeping Track: A Second Straight Burst Of FDA Approvals
The latest drug approval and development news from our US FDA Performance Tracker.
Novel Biologics Will Get Suffixes (Or At Least One Did)
US FDA's approval of Ultragenyx's Mepsevii (vestronidase alfa-vjbk) marks first novel biologic with a suffix, but 10 months after release of the naming guidance how – and even how widely – FDA will implement the policy remains uncertain.
Novel Biologics In US Might Not Start Getting Suffixes Until August
FDA has cleared four novel biologics without a suffix despite finalizing nonproprietary naming guidance; the agency requests sponsors submit proposed suffixes at the time a BLA is submitted.